Related references
Note: Only part of the references are listed.776PA PHASE 1/2 STUDY OF AT13387, A HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR IN COMBINATION WITH ABIRATERONE ACETATE (AA) AND PREDNISONE (P) IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) NO LONGER RESPONDING TO AA
R. Ferraldeschi et al.
ANNALS OF ONCOLOGY (2017)
Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors
Filip Janku et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
Roberta Ferraldeschi et al.
CANCER RESEARCH (2016)
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial
J. Rodon et al.
ANNALS OF ONCOLOGY (2015)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer
Ping Mu et al.
CANCER RESEARCH (2015)
Coordinate Loss of MAP3K7 and CHD1 Promotes Aggressive Prostate Cancer
Lindsey Ulkus Rodrigues et al.
CANCER RESEARCH (2015)
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Raphael Ceccaldi et al.
CANCER RESEARCH (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Wendy Onstenk et al.
EUROPEAN UROLOGY (2015)
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
Edward Samuel James et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).
Matthew Raymond Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sequencing of agents in castration-resistant prostate cancer
David Lorente et al.
LANCET ONCOLOGY (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
David T. Miyamoto et al.
SCIENCE (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
David I. Quinn et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
Lucas J. Brand et al.
ONCOTARGET (2015)
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
Michal Podrazil et al.
ONCOTARGET (2015)
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel
Pedram Kharaziha et al.
ONCOTARGET (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
R. Ferraldeschi et al.
ONCOGENE (2015)
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins
Paula Vainio et al.
Oncotarget (2015)
Prioritizing targets for precision cancer medicine
F. Andre et al.
ANNALS OF ONCOLOGY (2014)
Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression
Luis Alberto Henriquez-Hernandez et al.
BMC MEDICAL GENETICS (2014)
Novel drugs targeting the androgen receptor pathway in prostate cancer
Joaquin Mateo et al.
CANCER AND METASTASIS REVIEWS (2014)
A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
E. Gabriela Chiorean et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Abstract 2433:In vitroandin vivoantitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
Roberta Ferraldeschi et al.
CANCER RESEARCH (2014)
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao et al.
CELL (2014)
Circulating Tumor Cells: A Multifunctional Biomarker
Timothy A. Yap et al.
CLINICAL CANCER RESEARCH (2014)
Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
Prabhakar Rajan et al.
EUROPEAN UROLOGY (2014)
Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer
Kush Dalal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Sex Difference in Myelodysplastic Syndrome Survival and Balance in Randomized Clinical Trials
Tomas Radivoyevitch et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expanding Clinical Trial Networks in Pediatric Acute Lymphoblastic Leukemia
Stephen P. Hunger
JOURNAL OF CLINICAL ONCOLOGY (2014)
Diagnostic and Treatment Dilemma of Dual Pathology of Lung Cancer and Disseminated Tuberculosis
Nishitha Shetty et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Strategies for modern biomarker and drug development in oncology
Alan D. Smith et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Metabolomic Profiling identifies Biochemical Pathways Associated with Castration-Resistant Prostate Cancer
Akash K. Kaushik et al.
JOURNAL OF PROTEOME RESEARCH (2014)
N-terminal domain of the androgen receptor contains a region that can promote cytoplasmic localization
Javid A. Dar et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
John R. Prensner et al.
LANCET ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Diletta Di Mitri et al.
NATURE (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Stable RNA interference rules for silencing
Christof Fellmann et al.
NATURE CELL BIOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
canSAR: updated cancer research and drug discovery knowledgebase
Krishna C. Bulusu et al.
NUCLEIC ACIDS RESEARCH (2014)
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer
Shan Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Infiltration of CD8+Lymphocytes is an Independent Prognostic Factor of Biochemical Failure-Free Survival in Prostate Cancer
Nora Ness et al.
PROSTATE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer
Francesco Crea et al.
ONCOTARGET (2014)
Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway
Urszula L. McClurg et al.
ONCOTARGET (2014)
Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer
Julie N. Graff et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
S. K. Sandhu et al.
ANNALS OF ONCOLOGY (2013)
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
Hielke J. Meulenbeld et al.
BJU INTERNATIONAL (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma
Markus Brockmann et al.
CANCER CELL (2013)
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S. Antonarakis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
Nadeem A. Sheikh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
Lia Burkhardt et al.
CANCER RESEARCH (2013)
The Next-Generation Sequencing Revolution and Its Impact on Genomics
Daniel C. Koboldt et al.
CELL (2013)
Punctuated Evolution of Prostate Cancer Genomes
Sylvan C. Baca et al.
CELL (2013)
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Roberta Ferraldeschi et al.
CLINICAL CANCER RESEARCH (2013)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
Targeting transcription factors: promising new strategies for cancer therapy
Jennifer E. Yeh et al.
CURRENT OPINION IN ONCOLOGY (2013)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer
Stephanie A. Kovalchik et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
DNA Mismatch Repair in Prostate Cancer
Himisha Beltran
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer
Sabina Davidsson et al.
MODERN PATHOLOGY (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
A preclinical xenograft model of prostate cancer using human tumors
Mitchell G. Lawrence et al.
NATURE PROTOCOLS (2013)
Objective assessment of cancer genes for drug discovery
Mishal N. Patel et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
Christoph Plass et al.
NATURE REVIEWS GENETICS (2013)
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer
Zhou Du et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines
Raja Nhili et al.
NUCLEIC ACIDS RESEARCH (2013)
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Lina Gao et al.
PLOS ONE (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer
Alvaro Aytes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex
Zhijian Duan et al.
PROSTATE (2013)
FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants
Laura R. Bohrer et al.
PROSTATE (2013)
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer
Preethi Ravindranathan et al.
NATURE COMMUNICATIONS (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Ellen Heitzer et al.
GENOME MEDICINE (2013)
Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
Juan Miguel Mosquera et al.
NEOPLASIA (2013)
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K. N. Chi et al.
ANNALS OF ONCOLOGY (2012)
BAG-1 diversely affects steroid receptor activity
Regina T. Knapp et al.
BIOCHEMICAL JOURNAL (2012)
Metastatic castrate-resistant prostate cancer: dawn of a new age of management
Susan Masson et al.
BJU INTERNATIONAL (2012)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice
Jo Waaler et al.
CANCER RESEARCH (2012)
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings
Shancheng Ren et al.
CELL RESEARCH (2012)
Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors
Longjiang Shao et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group
Glenn Liu et al.
CLINICAL GENITOURINARY CANCER (2012)
Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue
Jennifer A. Fairley et al.
CURRENT DRUG TARGETS (2012)
Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
Winald R. Gerritsen et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
David Olmos et al.
LANCET ONCOLOGY (2012)
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
Robert W. Ross et al.
LANCET ONCOLOGY (2012)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis et al.
LANCET ONCOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Jenna L. Riffell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer
W. Liu et al.
ONCOGENE (2012)
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
S. Huang et al.
ONCOGENE (2012)
Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM
Dejuan Kong et al.
PLOS ONE (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy
Samuel R. Denmeade et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer et al.
CANCER DISCOVERY (2012)
ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen Receptors
Shinichi Yamashita et al.
NEOPLASIA (2012)
Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer
Paula Vainio et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors
Peter C. Hollenhorst et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
J. Chad Brenner et al.
CANCER CELL (2011)
Androgen receptor and its splice variants in prostate cancer
Simon Haile et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Circulating Tumor Cells as Biomarkers in Prostate Cancer
Daniel C. Danila et al.
CLINICAL CANCER RESEARCH (2011)
A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
David S. Hong et al.
CLINICAL CANCER RESEARCH (2011)
A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
Simon Pacey et al.
CLINICAL CANCER RESEARCH (2011)
Alternatively spliced androgen receptor variants
Scott M. Dehm et al.
ENDOCRINE-RELATED CANCER (2011)
Exosomes as Biomarker Treasure Chests for Prostate Cancer
Diederick Duijvesz et al.
EUROPEAN UROLOGY (2011)
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
Christiane M. Robbins et al.
GENOME RESEARCH (2011)
Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC)
G. Sonpavde et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study
Chia-Hsuin Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Roberto Pili et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
S. P. Anthony et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
ERG gene rearrangements are common in prostatic small cell carcinomas
Tamara L. Lotan et al.
MODERN PATHOLOGY (2011)
The genomic complexity of primary human prostate cancer
Michael F. Berger et al.
NATURE (2011)
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Philip M. Reaper et al.
NATURE CHEMICAL BIOLOGY (2011)
The changing therapeutic landscape of castration-resistant prostate cancer
Timothy A. Yap et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
RNA sequencing: advances, challenges and opportunities
Fatih Ozsolak et al.
NATURE REVIEWS GENETICS (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
Nicola J. Clegg et al.
PLOS ONE (2011)
YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
Said Rahim et al.
PLOS ONE (2011)
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Emma Hornberg et al.
PLOS ONE (2011)
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
Akash Kumar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Snapshot of the Expression Signature of Androgen Receptor Splicing Variants and Their Distinctive Transcriptional Activities
Rong Hu et al.
PROSTATE (2011)
Exploring the Genomes of Cancer Cells: Progress and Promise
Michael R. Stratton
SCIENCE (2011)
Therapeutic Targeting of SPINK1-Positive Prostate Cancer
Bushra Ateeq et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
William K. Oh et al.
UROLOGY (2011)
Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
Himisha Beltran et al.
CANCER DISCOVERY (2011)
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
A. H. M. Reid et al.
BRITISH JOURNAL OF CANCER (2010)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu et al.
CANCER CELL (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
Masanori Noguchi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform
Daniel Summerer et al.
GENOMICS (2010)
Systematic Structure-Function Analysis of Androgen Receptor Leu701 Mutants Explains the Properties of the Prostate Cancer Mutant L701H
Dennis J. van de Wijngaart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.
S. J. Hotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Translating cancer research into targeted therapeutics
J. S. de Bono et al.
NATURE (2010)
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Nallasivam Palanisamy et al.
NATURE MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Biases in Illumina transcriptome sequencing caused by random hexamer priming
Kasper D. Hansen et al.
NUCLEIC ACIDS RESEARCH (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine
Tracy Tucker et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors
F. Xu et al.
CANCER GENE THERAPY (2009)
Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
Kristiina Iljin et al.
CLINICAL CANCER RESEARCH (2009)
Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications
Marwan K. Tayeh et al.
GENETICS IN MEDICINE (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity
G. Attard et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
Philippe O. Gannon et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
ETS rearrangements and prostate cancer initiation
Brett S. Carver et al.
NATURE (2009)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar et al.
NATURE (2009)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Brett S. Carver et al.
NATURE GENETICS (2009)
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma
Hayriye V. Erkizan et al.
NATURE MEDICINE (2009)
Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G plus C)-biased genomes
Iwanka Kozarewa et al.
NATURE METHODS (2009)
RNA-Seq: a revolutionary tool for transcriptomics
Zhong Wang et al.
NATURE REVIEWS GENETICS (2009)
PSA as an intermediate end point in clinical trials
Gerhardt Attard et al.
NATURE REVIEWS UROLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
C. A. Crane et al.
ONCOGENE (2009)
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
Yang Zong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A Novel, Spontaneously Immortalized, Human Prostate Cancer Cell Line, Bob, Offers a Unique Model for Pre-Clinical Prostate Cancer Studies
Gerhardt Attard et al.
PROSTATE (2009)
Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-I+
Karen S. Sfanos et al.
PROSTATE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
G. Attard et al.
BRITISH JOURNAL OF CANCER (2008)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
The role of SPINK1 in ETS rearrangement-negative prostate cancers
Scott A. Tomlins et al.
CANCER CELL (2008)
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients
Ilona N. Holcomb et al.
CANCER RESEARCH (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer
Bharathi Laxman et al.
CANCER RESEARCH (2008)
Dissecting prostate carcinogenesis through ETS gene rearrangement studies:: implications for anticancer drug development
G. Attard et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Next-generation DNA sequencing
Jay Shendure et al.
NATURE BIOTECHNOLOGY (2008)
Substantial biases in ultra-short read data sets from high-throughput DNA sequencing
Juliane C. Dohm et al.
NUCLEIC ACIDS RESEARCH (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Role of the TMPRSS2-ERG gene fusion in prostate cancer
Arul M. Chinnaiyan
NEOPLASIA (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
New prostate cancer drug - Prostate cancer's day in the sun
Gerhardt Attard et al.
BRITISH MEDICAL JOURNAL (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Selective role of an NH2-Terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion-independent prostate cancer cells
Scott M. Dehm et al.
CANCER RESEARCH (2007)
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence
Stephen J. Libertini et al.
CANCER RESEARCH (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer
Elahe A. Mostaghel et al.
CANCER RESEARCH (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Inactivation of Apc in the mouse prostate causes prostate carcinoma
Katia J. Bruxvoort et al.
CANCER RESEARCH (2007)
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
Daniel R. Rhodes et al.
NEOPLASIA (2007)
Analysis of extended genomic rearrangements in oncological research
L. De Lellis et al.
ANNALS OF ONCOLOGY (2007)
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators
Haley Hieronymus et al.
CANCER CELL (2006)
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy
S. A. North et al.
JOURNAL OF UROLOGY (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Quantitative comparison of EST libraries requires compensation for systematic biases in cDNA generation
DL Liu et al.
BMC BIOINFORMATICS (2006)
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
T Burgess et al.
CANCER RESEARCH (2006)
Secondary hormonal therapy for advanced prostate cancer
JS Lam et al.
JOURNAL OF UROLOGY (2006)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells
T Hara et al.
PROSTATE (2005)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
ZB Chen et al.
NATURE (2005)
Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance
A Ayhan et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
J Bartkova et al.
NATURE (2005)
Poly(ADP-ribose) polymerase-1 and ionizing radiation: Sensor, signaller and therapeutic target
AJ Chalmers
CLINICAL ONCOLOGY (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease
PA McArdle et al.
BRITISH JOURNAL OF CANCER (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ONCOMINE: A cancer microarray database and integrated data-mining platform
DR Rhodes et al.
NEOPLASIA (2004)
Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans
A Bélanger et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2003)
Hsp90 as a therapeutic target in prostate cancer
DB Solit et al.
SEMINARS IN ONCOLOGY (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Dissemination and growth of cancer cells in metastatic sites
AF Chambers et al.
NATURE REVIEWS CANCER (2002)
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
M Mercader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
JS Sack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
